摘要
急性淋巴细胞白血病(ALL)是迄今为止儿童最常见的恶性肿瘤,免疫治疗方法将明显改变未来ALL患儿的治疗模式,包括双特异性抗体和嵌合抗原受体T细胞(CAR-T)在内的免疫疗法已被证明能够增强难治或复发B-ALL 患儿的免疫应答,并提高疾病的治愈率和患儿的生活质量。本文重点介绍双特异性抗体-贝林妥和CAR-T在儿童ALL中的临床研究和相关进展。
Acute lymphoblastic leukemia (ALL) is by far the most common malignant in children.Immunotherapy will obviously change the treatment mode of pediatric with ALL in the future.Immunotherapy including bispecific T-cell engagers and chimeric antigen receptor T cells has been demonstrated to be capable of enhancing the immune response in pediatric patients with refractory or relapsed B-ALL,and improving the cure rate of the disease and patients’ quality of life.This article focuses on the clinical research and related progress of bispecific antibodies-Blinatumomab and CAR-T in children with ALL.
作者
陈云
CHEN Yun(Tianjin Children’s Hospital,Tianjin 300134,China)
出处
《中外医学研究》
2022年第32期180-184,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
